Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

FTSE looks set for third straight week of gains

Published 25/11/2016, 09:53
© Reuters. A worker shelters from the rain as he passes the London Stock Exchange in London
UK100
-
GS
-
LLOY
-
ATLN
-
DBKGn
-
AZN
-
RIO
-
JNJ
-

By Alistair Smout

LONDON (Reuters) - Britain's top share index looked set for a third straight week of gains on Friday, with its heavily weighted commodity sector benefiting from bets on rising inflation even as a broader equity rally stalled.

The FTSE 100 (FTSE), was flat on Friday morning, hindered by a drop in banks, after gaining 0.8 percent so far this week.

Markets, which had been nervous over the prospect of Donald Trump winning the U.S. election, have rallied since his victory as his plans for higher infrastructure spending and fiscal stimulus have boosted prospects for growth and inflation. That has helped commodity stocks in particular, seen as a hedge against inflation and benefiting from faster growth in industrial output.

Global miner Rio Tinto (L:RIO) was the top riser on the index on Friday, up 1.5 percent.

Its chief executive said that the election of Trump could boost commodities demand, and the miner also benefited from target price upgrades by Deutsche Bank (DE:DBKGn) and JP Morgan after its capital markets day.

AstraZeneca (L:AZN) was up 1.2 percent as the pharmaceutical sector was in demand. Traders linked the move in AstraZeneca to a report that U.S. healthcare firm Johnson & Johnson (N:JNJ) was interested in buying Switzerland's Actelion (S:ATLN), sparking bets on further M&A in the sector.

AstraZeneca has shed more than 20 percent since early August, hit initially by concerns that a victory for Hillary Clinton in the U.S. election would result in more regulation for drugmakers, and more recently by warnings from its CEO on persistent pricing pressures as well as uncertainty about Trump's healthcare policy.

However, traders said that the reported bid from J&J for Actelion was evidence that there could still be support from M&A in the sector following the election.

"Bid speculation in AstraZeneca is likely to return. There was a huge pullback in their shares, and you have to see this as an opportunity," Zeg Choudhry, managing director at broker LONTRAD, said.

Lloyds (L:LLOY) was the biggest loser among bank stocks, falling around 1 percent.

"We are Sell-rated on Lloyds due to further asset margin headwinds," analysts at Goldman Sachs (NYSE:GS) said in a note, looking at British banks ahead of Bank of England stress tests.

It said that the stress tests would be the toughest so far, though the sector was in a much improved starting position compared to previous years.

© Reuters. A worker shelters from the rain as he passes the London Stock Exchange in London

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.